These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 23402677)

  • 1. Early treatment with high-dose interferon beta-1a reverses cognitive and cortical plasticity deficits in multiple sclerosis.
    Mori F; Kusayanagi H; Buttari F; Centini B; Monteleone F; Nicoletti CG; Bernardi G; Di Cantogno EV; Marciani MG; Centonze D
    Funct Neurol; 2012; 27(3):163-8. PubMed ID: 23402677
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of immunomodulatory treatment with subcutaneous interferon beta-1a on cognitive decline in mildly disabled patients with relapsing-remitting multiple sclerosis.
    Patti F; Amato MP; Bastianello S; Caniatti L; Di Monte E; Ferrazza P; Goretti B; Gallo P; Morra VB; Lo Fermo S; Picconi O; Tola MR; Trojano M;
    Mult Scler; 2010 Jan; 16(1):68-77. PubMed ID: 19995846
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in magnetic resonance imaging disease measures over 3 years in mildly disabled patients with relapsing-remitting multiple sclerosis receiving interferon β-1a in the COGnitive Impairment in MUltiple Sclerosis (COGIMUS) study.
    Bastianello S; Giugni E; Amato MP; Tola MR; Trojano M; Galletti S; Luccichenti G; Quarantelli M; Picconi O; Patti F;
    BMC Neurol; 2011 Oct; 11():125. PubMed ID: 21999142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of subcutaneous interferon β-1a in relapsing-remitting multiple sclerosis: further outcomes from the IMPROVE study.
    De Stefano N; Sormani MP; Stubinski B; Blevins G; Drulovic JS; Issard D; Shotekov P; Gasperini C
    J Neurol Sci; 2012 Jan; 312(1-2):97-101. PubMed ID: 21880336
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study.
    Khatri B; Barkhof F; Comi G; Hartung HP; Kappos L; Montalban X; Pelletier J; Stites T; Wu S; Holdbrook F; Zhang-Auberson L; Francis G; Cohen JA;
    Lancet Neurol; 2011 Jun; 10(6):520-9. PubMed ID: 21571593
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of subcutaneous interferon β-1a on MRI outcomes in a randomised controlled trial of patients with clinically isolated syndromes.
    De Stefano N; Comi G; Kappos L; Freedman MS; Polman CH; Uitdehaag BM; Hennessy B; Casset-Semanaz F; Lehr L; Stubinski B; Jack DL; Barkhof F
    J Neurol Neurosurg Psychiatry; 2014 Jun; 85(6):647-53. PubMed ID: 24292999
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quality of life, depression and fatigue in mildly disabled patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon beta-1a: 3-year results from the COGIMUS (COGnitive Impairment in MUltiple Sclerosis) study.
    Patti F; Amato MP; Trojano M; Bastianello S; Tola MR; Picconi O; Cilia S; Cottone S; Centonze D; Gasperini C;
    Mult Scler; 2011 Aug; 17(8):991-1001. PubMed ID: 21502310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial.
    Mikol DD; Barkhof F; Chang P; Coyle PK; Jeffery DR; Schwid SR; Stubinski B; Uitdehaag B;
    Lancet Neurol; 2008 Oct; 7(10):903-14. PubMed ID: 18789766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Magnetization transfer ratio in new MS lesions before and during therapy with IFNbeta-1a.
    Kita M; Goodkin DE; Bacchetti P; Waubant E; Nelson SJ; Majumdar S
    Neurology; 2000 May; 54(9):1741-5. PubMed ID: 10802778
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized study of once-weekly interferon beta-1la therapy in relapsing multiple sclerosis: three-year data from the OWIMS study.
    Freedman MS; Francis GS; Sanders EA; Rice GP; O'Connor P; Comi G; Duquette P; Metz L; Murray TJ; Bouchard JP; Abramsky O; Pelletier J; O'Brien F; ;
    Mult Scler; 2005 Feb; 11(1):41-5. PubMed ID: 15732265
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of peginterferon β-1a exposure and Gd-enhanced lesion or T2 lesion response in relapsing-remitting multiple sclerosis patients.
    Hang Y; Hu X; Zhang J; Liu S; Deykin A; Nestorov I
    J Pharmacokinet Pharmacodyn; 2016 Aug; 43(4):371-83. PubMed ID: 27299457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and tolerability of intramuscular interferon beta-1a compared with subcutaneous interferon beta-1a in relapsing MS: results from PROOF.
    Minagara A; Murray TJ;
    Curr Med Res Opin; 2008 Apr; 24(4):1049-55. PubMed ID: 18315940
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduction in magnetic resonance imaging T2 burden of disease in patients with relapsing-remitting multiple sclerosis: analysis of 48-week data from the EVIDENCE (EVidence of Interferon Dose-response: European North American Comparative Efficacy) study.
    Traboulsee A; Al-Sabbagh A; Bennett R; Chang P; Li DK; ;
    BMC Neurol; 2008 Apr; 8():11. PubMed ID: 18426595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.
    La Mantia L; Di Pietrantonj C; Rovaris M; Rigon G; Frau S; Berardo F; Gandini A; Longobardi A; Weinstock-Guttman B; Vaona A
    Cochrane Database Syst Rev; 2014 Jul; (7):CD009333. PubMed ID: 25062935
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Subcutaneous interferon-beta-1a in the treatment of multiple sclerosis].
    Fertl E; Krichmayr M
    Wien Med Wochenschr; 2008; 158(3-4):98-109. PubMed ID: 18330526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination therapy with interferon beta-1a and doxycycline in multiple sclerosis: an open-label trial.
    Minagar A; Alexander JS; Schwendimann RN; Kelley RE; Gonzalez-Toledo E; Jimenez JJ; Mauro L; Jy W; Smith SJ
    Arch Neurol; 2008 Feb; 65(2):199-204. PubMed ID: 18071030
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of disease-modifying drugs on cortical lesions and atrophy in relapsing-remitting multiple sclerosis.
    Calabrese M; Bernardi V; Atzori M; Mattisi I; Favaretto A; Rinaldi F; Perini P; Gallo P
    Mult Scler; 2012 Apr; 18(4):418-24. PubMed ID: 21228025
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early MRI results and odds of attaining 'no evidence of disease activity' status in MS patients treated with interferon β-1a in the EVIDENCE study.
    Coyle PK; Reder AT; Freedman MS; Fang J; Dangond F
    J Neurol Sci; 2017 Aug; 379():151-156. PubMed ID: 28716230
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitative differences in the immunomodulatory effects of Rebif and Avonex in IFN-β 1a treated multiple sclerosis patients.
    Christophi GP; Christophi JA; Gruber RC; Mihai C; Mejico LJ; Massa PT; Jubelt B
    J Neurol Sci; 2011 Aug; 307(1-2):41-5. PubMed ID: 21658727
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subcutaneous interferon β-1a may protect against cognitive impairment in patients with relapsing-remitting multiple sclerosis: 5-year follow-up of the COGIMUS study.
    Patti F; Morra VB; Amato MP; Trojano M; Bastianello S; Tola MR; Cottone S; Plant A; Picconi O;
    PLoS One; 2013; 8(8):e74111. PubMed ID: 24137499
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.